China Gathers Research Intelligence For Next Five-Year Plan
This article was originally published in PharmAsia News
The organizers of 863 Program recently held a strategic seminar on biomedical devices, biochips and nano-biotechnology for China's 12th five-year plan. Experts analyzed the world's development trends of these fields, examined key local academic institutions' research directions, as well as forecast the major requirements and progress of the sector during the five-year plan. Top executives from venture capitalists Morgan Stanley, WI Harper Group and Japan's SoftBank pointed out that China's life sciences research focus is in line with global market trends. They suggested that the next step should emphasize the commercialization of scientific achievements and their clinical applications. (Click here for more - Chinese Language)
You may also be interested in...
While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.
New chief medical officers take up positions at Abeona Therapeutics, Akcea Therapeutics and Oncologie, while there are new CFOs at Affimed, NGM Biopharmaceuticals, Phathom Pharmaceuticals, Oncologie and Syndax Pharmaceuticals.
Consumers in the UK can now self-select a version of Infirst's lipid-driven ibuprofen Flarin brand.